Here we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
Science translational medicine 6.224 (2014): 224ra25-224ra25.
Davila, Marco L., et al
The article discussed the efficacy and toxicity Management especially for cytokine release syndrome (CRS) management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. The paper shows results of treating advanced acute lymphoblastic leukemia with autologous T cells modified with a CD19-specific CAR containing the CD28 and CD3z signaling domains. An algorithm for identifying and managing patients with cytokine release syndrome is provided.
Molecular Therapy 23.10 (2015): 1600-1610.
VanSeggelen, Heather, et al.
A nagetive results in mice of CAR-T therapy that targ NKG2D ligands. This article concludes that while NKG2D ligands may be useful targets for immunotherapy, the pursuit of NKG2D-based CAR-T cell therapies should be undertaken with caution.
Blood 127, no. 26 (2016): 3321-3330.
Brudno, Jennifer N., and James N. Kochenderfer.
This review describes the toxicities maily of cytokine release syndrome (CRS) caused by CAR T cells and reviews the published approaches used to manage toxicities. The review present guidelines for treating patients experiencing CRS and other adverse events following CAR T-cell therapy.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION